Originally published as JCO Early Release 10.1200/JCO.2005.03.0239 on April 24 2006

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Han, J.-Y. Articles by Soo Lee, J. Search for Related Content PubMed PubMed Citation Articles by Han, J.-Y. Articles by Soo Lee, J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB CIS-DIAMINEDICHLOROPLATINUM PLATINUM COMPOUNDS Medline Plus Health Information Lung Cancer Related Articles Related Editorial Social Bookmarking                            What's this?

Comprehensive Analysis of UGT1A Polymorphisms Predictive for Pharmacokinetics and Treatment Outcome in Patients With Non–Small-Cell Lung Cancer Treated With Irinotecan and Cisplatin

Ji-Youn Han, Hyeong-Seok Lim, Eun Soon Shin, Yeon-Kyeong Yoo, Yong Hoon Park, Jong-Eun Lee, In-Jin Jang, Dae Ho Lee, Jin Soo Lee

From the Research Institute and Hospital, National Cancer Center, Goyang; Research Institute of Aging Science, Yonsei University; Department of Pharmacology, Seoul National University College of Medicine, Seoul, Korea

Address reprint requests to Jin Soo Lee, MD, Lung Cancer Branch, National Cancer Center, 809 Madu-dong, Ilsan-gu, Goyang, Gyeonggi 411-769, Korea; e-mail:jslee{at}ncc.re.kr

Purpose To determine whether uridine diphosphate-glucuronosyltransferase 1A1, UGT1A7, and UGT1A9 polymorphisms affect the pharmacokinetics (PK) of irinotecan and treatment outcome of Korean patients with advanced non–small-cell lung cancer (NSCLC).

Methods Eighty-one patients with advanced NSCLC were treated with irinotecan (80 mg/m²) on day 1 and 8 and cisplatin (60 mg/m²) on day 1 intravenously of each 3-week cycle. Genomic DNA was extracted from peripheral blood and genotyped using direct sequencing. We analyzed the association of UGT1A genotypes with irinotecan PK and clinical outcomes. All statistical tests were two-sided.

Results In genotype-PK association analysis, UGT1A1*6/*6 (n = 6), UGT1A7*3/*3 (n = 6), and UGT1A9-118(dT)_9/9 (n = 11) were associated with significantly lower area under the time-concentration curve (AUC) SN-38G to SN-38 (AUC_SN-38G/AUC_SN-38) ratio (P = .002, P = .009, and P = .001, respectively). In linkage disequilibrium analysis, the UGT1A7 variants were highly linked with the UGT1A1*6 (D' = 0.85, r² = 0.63) and UGT1A9*22 (D' = 0.95, r² = 0.88), which was substantiated in haplotype analysis. Patients with UGT1A1*6/*6 had lower tumor response and higher incidence of severe neutropenia. UGT1A9-118(dT)_9/9 also showed a trend for high incidence of severe diarrhea, but not tumor response. In survival analysis, patients with UGT1A1*6/*6 had significantly shorter progression-free survival (P = .001) and overall survival (P = .017).

Conclusion These findings suggest that UGT1A1*6 and UGT1A9*22 genotypes may be important for SN-38 glucuronidation and associate with irinotecan-related severe toxicity. Specifically, UGT1A1*6 might be useful for predicting tumor response and survival outcome of Korean patients with NSCLC treated with irinotecan-based chemotherapy.

This study was supported by Grants No. 0210130, 0210140, 0510140, and 0510080 from the National Cancer Center, Goyang, Korea.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Irinogenetics: What Is the Right Star?
  Federico Innocenti, Everett E. Vokes, and Mark J. Ratain
  JCO 2006 24: 2221-2224 [Full Text]

This article has been cited by other articles:

				R. H.J. Mathijssen and H. Gurney Irinogenetics: How Many Stars Are There in the Sky? J. Clin. Oncol., June 1, 2009; 27(16): 2578 - 2579. [Full Text] [PDF]

				E. Cecchin, F. Innocenti, M. D'Andrea, G. Corona, E. De Mattia, P. Biason, A. Buonadonna, and G. Toffoli Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan J. Clin. Oncol., May 20, 2009; 27(15): 2457 - 2465. [Abstract] [Full Text] [PDF]

				R. S. Huang and M. J. Ratain Pharmacogenetics and pharmacogenomics of anticancer agents CA Cancer J Clin, January 1, 2009; 59(1): 42 - 55. [Abstract] [Full Text] [PDF]

				W. Ichikawa, K. Araki, K.-I. Fujita, W. Yamamoto, H. Endo, F. Nagashima, R. Tanaka, T. Miya, K. Kodama, Y. Sunakawa, et al. Re: UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters J Natl Cancer Inst, February 6, 2008; 100(3): 224 - 225. [Full Text] [PDF]

				P. J. O'Dwyer and R. B. Catalano Uridine Diphosphate Glucuronosyltransferase (UGT) 1A1 and Irinotecan: Practical Pharmacogenomics Arrives in Cancer Therapy J. Clin. Oncol., October 1, 2006; 24(28): 4534 - 4538. [Full Text] [PDF]

				F. Innocenti, E. E. Vokes, and M. J. Ratain Irinogenetics: What Is the Right Star? J. Clin. Oncol., May 20, 2006; 24(15): 2221 - 2224. [Full Text] [PDF]